Different autoimmune sits at the center of this dementia and brain health question.
A single infusion of CD19 CAR T-cell therapy — a treatment originally built to fight blood cancers — is now pushing three different autoimmune diseases into remission at the same time. In a landmark case series published in the New England Journal of Medicine in February 2024, researchers at the University of Erlangen in Germany treated 15 patients who had severe, treatment-resistant lupus, inflammatory myositis, or systemic sclerosis. Every single one of them went into remission or experienced major symptom reduction. Every single one of them stopped taking immunosuppressive drugs entirely.
Their autoantibodies disappeared. That is not a typo, and it is not early-stage speculation. Those results held at a median follow-up of 15 months, and the therapy is now being tested at larger scale by Bristol Myers Squibb, Cabaletta Bio, and the University of Chicago, among others. For the millions of people living with autoimmune conditions — and for their families, many of whom are also navigating dementia care and other chronic health challenges — this represents something genuinely new: not another drug to manage symptoms, but a potential one-time reset of the immune system itself. This article breaks down how CAR T-cell therapy works against autoimmune disease, what the clinical data actually shows across all three conditions, what the safety risks look like, where larger trials stand today, and what this could eventually mean for patients who have run out of options.
Table of Contents
- How Does One Drug Treat Three Different Autoimmune Conditions at Once?
- What the Erlangen Case Series Actually Showed — And Where the Limits Are
- Bristol Myers Squibb’s Breakfree-1 Trial Scales Up the Evidence
- Who Else Is Developing CAR T Therapy for Autoimmune Disease — And How the Approaches Differ
- Safety Risks and Why This Is Not Ready for Everyone Yet
- What This Means for People Managing Multiple Chronic Conditions
- Where This Is Headed and What to Watch For
- Conclusion
- Frequently Asked Questions
How Does One Drug Treat Three Different Autoimmune Conditions at Once?
The key is that lupus, inflammatory myositis, and systemic sclerosis share a common villain: B cells gone wrong. B cells are immune cells that normally produce antibodies to fight infection. In autoimmune diseases, certain B cells malfunction and produce autoantibodies — proteins that attack the body’s own tissues. In lupus, they target joints, kidneys, and skin. In myositis, they attack muscle. In systemic sclerosis, they drive fibrosis and hardening of the skin and internal organs. Different targets, same underlying engine.
CD19 CAR T-cell therapy works by engineering a patient’s own T cells to hunt down and destroy cells carrying the CD19 protein, which sits on the surface of B cells. Once infused, these modified T cells wipe out the patient’s B cell population — including the rogue cells producing autoantibodies. When B cells eventually re-emerge weeks to months later, they come back with what researchers call a “naive phenotype.” They are, in effect, fresh cells that have not learned to attack the body. It amounts to rebooting the immune system’s B cell compartment from scratch. Compare this to conventional autoimmune treatment, which typically involves broad immunosuppression — drugs like methotrexate, mycophenolate, or rituximab that dampen the immune system across the board and must be taken indefinitely. Those drugs manage symptoms. They do not reset anything. CAR T-cell therapy, at least in the data so far, appears to do something fundamentally different: eliminate the root cause and let the immune system rebuild correctly, all from a single infusion.
What the Erlangen Case Series Actually Showed — And Where the Limits Are
The University of Erlangen study, led by rheumatologist Georg Schett, treated 15 patients with refractory autoimmune disease — meaning standard therapies had already failed them. Eight had systemic lupus erythematosus, three had idiopathic inflammatory myositis, and four had systemic sclerosis. Each received a single infusion of CD19-targeted CAR T cells. The results were striking by any clinical standard. All eight lupus patients achieved DORIS remission, considered the gold standard for lupus response. All three myositis patients hit an ACR-EULAR major clinical response. All four systemic sclerosis patients showed decreased disease activity on the EUSTAR activity index. Autoantibodies vanished across the board. However, there are real limitations to keep in mind.
Fifteen patients is a very small sample. There was no control group, which means we cannot fully separate the effect of the therapy from other variables. The follow-up window ranged from 4 to 29 months — long enough to be encouraging, but not long enough to know whether remission holds for years or whether some patients will eventually relapse. We do not yet know if the naive B cells that return will stay naive indefinitely or whether, in some patients, autoimmunity could reignite over time. These are exactly the questions that larger trials are now designed to answer. It is also worth noting that CAR T-cell therapy requires lymphodepletion chemotherapy before infusion — a process that temporarily wipes out much of the immune system. That makes patients vulnerable to infection during the recovery window. This is not a casual outpatient procedure. It demands specialized centers, careful monitoring, and patients healthy enough to tolerate the preparatory regimen.
Bristol Myers Squibb’s Breakfree-1 Trial Scales Up the Evidence
The Erlangen results opened the door. Bristol Myers Squibb walked through it. Their Breakfree-1 Phase 1 trial is testing BMS-986353, an autologous CD19-targeted NEX-T CAR T cell therapy, across all three autoimmune conditions — lupus, systemic sclerosis, and inflammatory myositis — in an open-label, multicenter design. As of data presented at ACR Convergence 2025 in October, 71 patients had been treated across all three cohorts. That is nearly five times the size of the Erlangen series. The results tracked closely with the earlier findings.
Ninety-four percent of evaluable patients remained off chronic immunosuppressive therapy at the time of analysis. Researchers observed robust CAR T cell expansion, complete B cell depletion, and the same re-emergence of naive B cell populations seen in the Erlangen work. The safety profile was described as acceptable — most adverse events occurred shortly after infusion and resolved quickly, consistent with what is already known from CAR T use in oncology. BMS has since launched a Phase 2 study called Breakfree-SLE, focused specifically on lupus, which is currently recruiting patients. The move from Phase 1 to Phase 2 matters because it signals that the company believes the safety and efficacy signals are strong enough to invest in larger, more rigorous testing. For a therapy this complex and expensive to manufacture, that is a significant commitment.
Who Else Is Developing CAR T Therapy for Autoimmune Disease — And How the Approaches Differ
The field is moving fast, and not every company is taking the same path. Cabaletta Bio is running five separate Phase 1/2 studies under its RESET program, testing its therapy rese-cel across lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris. That broader scope is notable — it tests whether the B cell reset concept extends to autoimmune conditions beyond the original three. Perhaps the most intriguing alternative approach comes from Calibr-Skaggs at Scripps Research.
Their program, CLBR001 combined with SWI019, uses a switchable CAR-T system that does not require chemotherapy preconditioning. The FDA cleared their IND application for a Phase 1 trial covering myositis, systemic sclerosis, lupus, and rheumatoid arthritis. If the no-chemo approach works, it could dramatically lower the barrier to treatment — making CAR T-cell therapy accessible to patients who cannot tolerate lymphodepletion, including older adults and those with other serious health conditions like dementia or cardiovascular disease. The University of Chicago Medicine has also launched a Phase 2 clinical trial studying CAR T-cell therapy across the same three autoimmune conditions as the Erlangen work. Having an academic medical center run its own trial is important because it generates data independent of pharmaceutical company interests and can explore questions that may not align with commercial priorities.
Safety Risks and Why This Is Not Ready for Everyone Yet
The most common side effect in the Erlangen series was cytokine release syndrome, or CRS — an inflammatory response triggered when CAR T cells activate and begin killing their targets. Ten of the 15 patients experienced Grade 1 CRS, which is the mildest form, involving symptoms like fever and fatigue. One patient had Grade 2 CRS. No severe adverse events were reported. That safety record is notably better than what is seen in CAR T therapy for cancer, where CRS can be life-threatening — likely because the B cell burden in autoimmune disease is much lower than the tumor burden in blood cancers. But mild side effects in 15 patients do not guarantee mild side effects in 15,000. As trials scale up, rarer complications will emerge.
There is also the practical concern of infection risk during the period between lymphodepletion chemotherapy and immune reconstitution. Patients are functionally immunocompromised during this window, and for someone already managing other chronic conditions, that vulnerability is not trivial. Cost and access present another significant barrier. Current autologous CAR T-cell therapies for cancer cost between $300,000 and $500,000 per infusion in the United States. The manufacturing process — extracting a patient’s T cells, engineering them, expanding them, and reinfusing them — takes weeks and requires specialized facilities. If CAR T therapy gains approval for autoimmune diseases, insurers will face difficult questions about coverage, particularly for conditions that are not immediately life-threatening. Until manufacturing costs come down or off-the-shelf allogeneic versions become available, access will remain limited.
What This Means for People Managing Multiple Chronic Conditions
For families navigating dementia care alongside autoimmune disease, the potential of a one-time treatment that eliminates the need for daily immunosuppressive drugs is hard to overstate. Immunosuppressive medications carry their own cognitive and neurological side effects — brain fog, fatigue, increased infection risk — that can compound the challenges of caring for or living with dementia. A therapy that removes that drug burden, even in a subset of patients, could meaningfully improve quality of life.
Consider a patient with lupus who is also in the early stages of cognitive decline. Managing daily medications, attending frequent rheumatology appointments, and dealing with lupus flares all compete for the limited energy and executive function that dementia progressively erodes. If a single infusion could put lupus into sustained remission and eliminate the medication regimen, it would simplify that person’s care in ways that ripple outward to caregivers, family logistics, and overall health stability.
Where This Is Headed and What to Watch For
The next 18 to 24 months will be decisive. Phase 2 results from BMS, Cabaletta, and academic centers will tell us whether the remarkable early results hold up in larger, more diverse patient populations and over longer follow-up periods. The switchable CAR-T approach from Calibr-Skaggs, if it works without chemotherapy, could rewrite the accessibility equation entirely. And regulatory agencies will begin signaling how they plan to evaluate a therapy that was built for cancer but is being repurposed for chronic disease. What makes this moment different from past autoimmune “breakthroughs” is the consistency of the signal.
Multiple independent groups, using slightly different CAR T constructs, are seeing the same thing: deep remission, drug discontinuation, immune reset. That convergence of evidence, across three diseases and now across multiple trials, is harder to explain away as a fluke. It does not mean every patient will respond. It does not mean the remissions will last forever. But it does mean the field has crossed a threshold — from interesting theory to reproducible clinical reality.
Conclusion
CD19 CAR T-cell therapy has produced results across lupus, inflammatory myositis, and systemic sclerosis that would have seemed implausible five years ago. From the Erlangen case series showing all 15 patients in remission and off immunosuppression, to BMS’s 71-patient Breakfree-1 trial showing 94 percent of patients remaining drug-free, the data points in a consistent direction. The mechanism is elegant in its simplicity: destroy the malfunctioning B cells, let new ones grow back without the autoimmune programming, and achieve what amounts to a reboot of part of the immune system from a single infusion. The caveats are real — small sample sizes in the earliest data, unknown long-term durability, significant cost, and the need for chemotherapy preconditioning in most current approaches.
But with multiple Phase 2 trials now underway and alternative delivery methods in development that could eliminate the chemo requirement, the trajectory is clear. For people living with refractory autoimmune disease, particularly those managing additional chronic conditions, this is worth following closely. Talk to your rheumatologist about whether clinical trial enrollment might be appropriate. The best place to search for active trials is ClinicalTrials.gov, using the search terms “CAR T” and your specific autoimmune condition.
Frequently Asked Questions
What is CD19 CAR T-cell therapy?
It is a treatment in which a patient’s own T cells are extracted, genetically engineered to target the CD19 protein on B cells, and then infused back into the patient. The modified T cells seek out and destroy B cells, including the dysfunctional ones that produce autoantibodies driving autoimmune disease.
Is CAR T-cell therapy for autoimmune disease FDA approved?
No. As of early 2026, CAR T-cell therapy is FDA approved only for certain blood cancers. Its use in autoimmune diseases like lupus, myositis, and systemic sclerosis is still in clinical trials, with Phase 2 studies currently underway.
How long does remission last after CAR T-cell therapy for autoimmune disease?
In the Erlangen study, all 15 patients remained in remission at a median follow-up of 15 months, with the longest follow-up reaching 29 months. Longer-term durability data is still being collected through ongoing trials.
What are the side effects of CAR T-cell therapy in autoimmune patients?
The most common side effect is cytokine release syndrome, which was mild (Grade 1) in most patients in the Erlangen series. Patients also face temporary immune suppression due to the chemotherapy given before infusion, which increases infection risk during the recovery period.
Does CAR T-cell therapy require chemotherapy?
Most current protocols require lymphodepletion chemotherapy before the CAR T infusion to help the engineered cells expand. However, Calibr-Skaggs is developing a switchable CAR-T system that does not require chemotherapy preconditioning, which could make the therapy accessible to more patients.
Can older adults or people with dementia receive CAR T-cell therapy?
Clinical trials have specific eligibility criteria, and patients need to be healthy enough to tolerate the treatment process, including chemotherapy preconditioning in most current protocols. Older adults with significant comorbidities may face higher risks. The development of chemo-free approaches could eventually broaden eligibility.
You Might Also Like
- The Drug That Treats Both Type 1 and Type 2 Diabetes Differently
- This Drug Approved for One Condition Treats 12 Others Off-Label
- The Drug That Allows Transplant Patients to Eat Grapefruit Again
For more, see NIH MedlinePlus — dementia.
